Close
Almac
Achema middle east

Drug Research

Seven Indian Drugmakers Race To Develop Covid-19 Vaccine

Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E among domestic pharma firms working on the vaccines in India At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they...

BioInvent’s BI-1206 could improve treatment in several cancers

Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...

Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...

GSK and CureVac announce strategic mRNA technology collaboration

GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...

CMIC Group Establishes a New Biologic Contract Development and Manufacturing Business in Japan

CMIC HOLDINGS Co., Ltd. announced the establishment of CMIC BIO Co., Ltd. (hereafter CMIC BIO), a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in...

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate

CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of its partnership with Sichuan Clover Biopharmaceuticals, Inc to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover’s proprietary Trimer-Tag©...

Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies existing CDO partnership first established in 2018. “As we already have a track record of successful...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »